CNSX:VP Vodis Pharmaceuticals (VP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Vodis Pharmaceuticals Stock (CNSX:VP) Get Vodis Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume51,582 shsAverage Volume1,714 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Vodis Pharmaceuticals Inc. operates as an application stage company for producing medical marijuana. It operates in Canada and the United States. The company is based in Delta, Canada. Read More Receive VP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vodis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VP Stock News HeadlinesVP debate 'spin room' scene: Talking points and unscripted momentsOctober 22, 2024 | usatoday.comVice President Harris in ‘Excellent Health,’ Medical Report StatesOctober 14, 2024 | msn.comShocking AI prediction from the “Billionaire Whisperer"Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percent run, and Nvidia before it climbed more than 50,000 percent. Now Chaikin says a new AI data center technology using 99 percent less electricity, water, and space could accelerate scientific breakthroughs 360-fold, and one company behind it just flashed bullish in his system. See the full research and the ticker Chaikin is watching before this presentation goes offline.September 12 at 1:00 AM | Chaikin Analytics (Ad)Vance Confident, Walz Uneven in VP Debate Heavy on PolicyOctober 2, 2024 | wsj.comRead the full VP debate transcript from the Walz-Vance showdownOctober 2, 2024 | cbsnews.comAs Investigations Swirl, Another Adams Official ResignsSeptember 24, 2024 | nytimes.comTonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial OperationsSeptember 10, 2024 | markets.businessinsider.comKalVista Pharma Appoints Brian Piekos As New CFOSeptember 10, 2024 | markets.businessinsider.comSee More Headlines VP Stock Analysis - Frequently Asked Questions How do I buy shares of Vodis Pharmaceuticals? Shares of VP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vodis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vodis Pharmaceuticals investors own include Ampliphi Biosciences (APHB), Apellis Pharmaceuticals (APLS), Athersys (ATHX), Iovance Biotherapeutics (IOVA), Arbutus Biopharma (ABUS) and Aurora Cannabis (ACBFF). Industry, Sector and Symbol Stock ExchangeCNSX SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolCNSX:VP CIKN/A Webvodis.ca Phone778-990-8985FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (CNSX:VP) was last updated on 9/12/2026 by MarketBeat.com Staff. From Our PartnersThis 38 Dollar Fund Holds Every Major AI Stock and Pays WeeklyThe biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...Investors Alley | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe retirement income that answers “yes” when everything else says noTodd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...Eagle Publishing | Sponsored17 Nobel Prize winners… one startling warningOn July 13, 17 Nobel laureates including Bernanke, Krugman, and Stiglitz signed an 88-word letter warning that...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vodis Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vodis Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.